Skip to main content

Table 2 Major clinical characteristics and CD133 expression of EOC patients with vs. without CNS metastases

From: Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer

Parameter

No. of patients (%)

Pvalue

 

EOC w/ CNS metastases

EOC w/o CNS metastases

 

Age (yrs)

  

0.599

  <60

16 (55.2)

15 (48.4)

 

  > = 60

13 (44.8)

16 (51.6)

 

FIGO stage

  

0.666

  1,2

3 (10.3)

2 (6.5)

 

  3,4

26 (89.7)

29 (93.5)

 

Pathology of primary cancer

 

0.979†

  Serous

16 (55.2)

17 (54.8)

 

  Mucinous

2 (6.9)

2 (6.5)

 

  Endometrioid

2 (6.9)

2 (6.5)

 

  Clear cell

1 (3.4)

2 (6.5)

 

  Mixed epithelial

5 (17.2)

5 (16.1)

 

  Undifferentiated

3 (10.3)

3 (9.7)

 

Histological grade*

 

0.724

  1,2

5 (21.7)

4 (16.7)

 

  3,

18 (78.3)

20 (83.3)

 

Extent of surgical resection

 

0.572

  TAH + BSO

23 (79.3)

26 (83.9)

 

  Limited

5 (17.2)

5 (16.1)

 

  Biopsy

1 (3.4)

0 (0)

 

Lymph node metastasis

 

0.313

  Yes

18 (62.1)

23 (74.2)

 

  No

11 (37.9)

8 (25.8)

 

Ascites at the time of primary surgery

0.650

  Yes

19 (46.3)

22 (52.6)

 

  No

10 (53.7)

9 (47.4)

 

Adjuvant therapy

  

0.674

  Chemotherapy

25 (86.2)

24 (77.4)

 

  Chemotherapy + Radiotherapy

3 (10.3)

5 (16.1)

 

  None

1 (3.4)

2 (6.5)

 

Platinum sensitivity

 

0.516

  Sensitive

16 (57.1)

19 (65.5)

 

  Resistant

12 (42.9)

10 (34.5)

 

CD133 expression

 

0.018

  Negative

15 (51.7)

25 (80.6)

 

  Positive

14 (48.3)

6 (19.4)

 
  1. Abbreviations: TAH Total abdominal hysterectomy, BSO Bilateral salpingo-oophorectomy.
  2. *Where data were available.
  3. †P value was caculated by comparing serous vs. non-serous groups.